<DOC>
	<DOCNO>NCT00368654</DOCNO>
	<brief_summary>To evaluate whether short-term course methotrexate patient treat efalizumab ( Raptiva ) increase efficacy . The secondary objective study 1 ) evaluate efficacy Raptiva maintain clinical improvement induce short-term treatment combination therapy Raptiva methotrexate 2 ) evaluate safety short-term combination therapy Raptiva methotrexate .</brief_summary>
	<brief_title>Evaluate Whether Combination Therapy With Methotrexate Raptiva Psoriasis Patients Safe Increases Efficacy</brief_title>
	<detailed_description>The primary objective study evaluate whether short-term course methotrexate patient treat efalizumab ( Raptiva ) increase efficacy . The secondary objective study 1 ) evaluate efficacy Raptiva maintain clinical improvement induce short-term treatment combination therapy Raptiva methotrexate 2 ) evaluate safety short-term combination therapy Raptiva methotrexate . The design study gain good control disease process reduce potential toxicity begin treatment Raptiva add methotrexate patient improve significantly</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Moderate severe plaquetype psoriasis A candidate systemic therapy phototherapy Not use prescription systemic therapy psoriasis prior start study Not use efalizumab within 3 month prior start study We seek adult : Have moderate severe plaquetype psoriasis Are generally healthy Are hypersensitive RaptivaÂ® ( efalizumab ) component . Are pregnant lactate woman You : Be interview examine Have blood drawn Be inject study medication Hypersensitivity Raptiva component Pregnant lactate woman History liver disease abnormal liver enzymes History chronic infection malignancy History significant hematologic abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>